VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.14%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$204M
AUM Growth
+$15.9M
(+8.5%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
8.1%
Top 10 Holdings %
Top 10 Hldgs %
6.14%
Holding
488
New
66
Increased
245
Reduced
135
Closed
40
Top Buys
| 1 |
CrowdStrike
CRWD
|
$1.1M |
| 2 |
Netflix
NFLX
|
$1.03M |
| 3 |
Qualcomm
QCOM
|
$1.03M |
| 4 |
Royal Caribbean
RCL
|
$1M |
| 5 |
TJX Companies
TJX
|
$973K |
Top Sells
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
$1.11M |
| 2 |
Eli Lilly
LLY
|
$937K |
| 3 |
Freeport-McMoran
FCX
|
$933K |
| 4 |
Align Technology
ALGN
|
$933K |
| 5 |
Martin Marietta Materials
MLM
|
$930K |
Sector Composition
| 1 | Financials | 26.66% |
| 2 | Healthcare | 19.14% |
| 3 | Technology | 17.16% |
| 4 | Energy | 7.21% |
| 5 | Industrials | 6.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Rhythm Pharmaceuticals
RYTM
$6.78B
| $305K | 0.15% |
7,423
-1,451
| -16% | -$59.6K |
|
227
Agios Pharmaceuticals
AGIO
$2.09B
| $304K | 0.15% |
7,042
-9,353
| -57% | -$403K |
|
228
Lexicon Pharmaceuticals
LXRX
$396M
| $302K | 0.15% |
179,972
-113,120
| -39% | -$190K |
|
229
Apellis Pharmaceuticals
APLS
$3.55B
| $297K | 0.15% |
7,738
+436
| +6% | +$16.7K |
|
230
Zai Lab
ZLAB
$3.42B
| $290K | 0.14% |
16,727
+4,114
| +33% | +$71.3K |
|
231
BridgeBio Pharma
BBIO
$10.2B
| $288K | 0.14% |
11,357
+746
| +7% | +$18.9K |
|
232
Geron
GERN
$893M
| $286K | 0.14% |
67,490
+28,285
| +72% | +$120K |
|
|
ONC
233
BeOne Medicines Ltd. American Depositary Shares
ONC
$37.6B
| $282K | 0.14% |
1,979
-52
| -3% | -$7.42K |
|
234
Immunocore
IMCR
$1.87B
| $281K | 0.14% |
8,298
+2,336
| +39% | +$79.2K |
|
235
Novavax
NVAX
$1.28B
| $277K | 0.14% |
21,884
+6,656
| +44% | +$84.3K |
|
236
BioNTech
BNTX
$27B
| $276K | 0.14% |
3,431
-234
| -6% | -$18.8K |
|
237
PTC Therapeutics
PTCT
$4.55B
| $273K | 0.13% |
8,925
-4,880
| -35% | -$149K |
|
238
CRISPR Therapeutics
CRSP
$4.99B
| $273K | 0.13% |
5,047
-1,007
| -17% | -$54.4K |
|
239
Tarsus Pharmaceuticals
TARS
$2.43B
| $270K | 0.13% |
9,938
-9,990
| -50% | -$272K |
|
240
Moderna
MRNA
$9.78B
| $269K | 0.13% |
2,268
-2,169
| -49% | -$258K |
|
241
Esperion Therapeutics
ESPR
$540M
| $251K | 0.12% |
+113,178
| New | +$251K |
|
242
Alliance Resource Partners
ARLP
$2.94B
| $222K | 0.11% |
9,085
+6
| +0.1% | +$147 |
|
243
Clearway Energy Class C
CWEN
$3.38B
| $211K | 0.1% |
8,547
+1,828
| +27% | +$45.1K |
|
244
GeoPark
GPRK
$326M
| $209K | 0.1% |
19,079
-1,518
| -7% | -$16.6K |
|
245
Western Midstream Partners
WES
$14.5B
| $206K | 0.1% |
5,197
-1,224
| -19% | -$48.6K |
|
246
Camden Property Trust
CPT
$11.9B
| $202K | 0.1% |
1,847
+7
| +0.4% | +$764 |
|
247
Extra Space Storage
EXR
$31.3B
| $201K | 0.1% |
1,296
-5,022
| -79% | -$780K |
|
248
National Storage Affiliates Trust
NSA
$2.56B
| $201K | 0.1% |
4,866
+463
| +11% | +$19.1K |
|
249
Agree Realty
ADC
$8.08B
| $199K | 0.1% |
3,212
+336
| +12% | +$20.8K |
|
250
Innovative Industrial Properties
IIPR
$1.61B
| $199K | 0.1% |
1,820
+7
| +0.4% | +$765 |
|